Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an injectable solution for intravenous use. It is indicated for the treatment of serious Gram‑positive bacterial infections such as methicillin‑resistant Staphylococcus aureus (MRSA), community‑acquired pneumonia, and skin and soft‑tissue infections in adult patients.

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including both public and private healthcare institutions.

Linezolid is an oxazolidinone antibiotic used to treat infections caused by Gram‑positive bacteria. - Methicillin‑resistant Staphylococcus aureus (MRSA): effective in treating serious MRSA infections, including bacteremia and skin infections. - Community‑acquired pneumonia: used to manage pneumonia caused by susceptible Gram‑positive organisms. - Skin and soft‑tissue infections: indicated for complicated infections of the skin and underlying tissues caused by susceptible strains. - Gram‑positive bacterial infections: provides coverage for a broad range of susceptible Gram‑positive pathogens, including Streptococcus species.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Headache: transient headache reported during therapy. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding. - Peripheral neuropathy: nerve damage causing numbness or tingling, especially with prolonged use. - Serum lactic acidosis: rare metabolic disturbance requiring immediate medical attention. - Optic neuropathy: vision changes due to optic nerve involvement, may be irreversible.

When prescribing Linezolid, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust monitoring as accumulation may occur in severe kidney dysfunction. - Hepatic dysfunction: use caution in patients with liver disease, monitoring liver enzymes. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Prolonged therapy: monitor for hematologic abnormalities such as thrombocytopenia. - Pregnancy and lactation: assess risk‑benefit, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): concurrent use can increase risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Rifampin: may reduce linezolid plasma concentrations, potentially decreasing efficacy. - Theophylline: possible increase in theophylline levels, monitor for toxicity.